The European Medicines Agency (EMA) approved on Wednesday an adapted version of the anti-Covid vaccine from Pfizer et BioNTech to combat infection by a widespread subvariant of the virus in winter.
Although since the beginning of May the World Health Organization no longer considers Covid-19 a global health emergency, the virus continues to circulate in all countries, and new strains continue to emerge.
The EMA announced in a statement that “recommended authorizing a vaccine (…) adapted to target the subvariant omicron XBB.1.5″.
The European regulator had recommended in June that the vaccines be updated to target the XBB strain of the virus that has become dominant in Europe and other parts of the world.
The new approved messenger RNA technology vaccine, called Comirnaty Omicron XBB.1.5, is intended to prevent Covid-19 in adults and children from six months of age.
“As Omicron BB.1.5 is closely linked to other variants currently in circulation, the vaccine should help maintain protection against (…) those other variants”according to the EMA.
Source: AFP
Source: Gestion
Ricardo is a renowned author and journalist, known for his exceptional writing on top-news stories. He currently works as a writer at the 247 News Agency, where he is known for his ability to deliver breaking news and insightful analysis on the most pressing issues of the day.
